During Wednesday’s Current trade, Shares of Alcatel Lucent SA (ADR) (NYSE:ALU), gain 0.55% to $3.68.
Alcatel-Lucent (ALU) and China Mobile, the world’s largest mobile communications service provider, have conducted the industry’s first field trial of a virtualized radio access network-based architecture based on network functions virtualization (NFV) technology.
The trial – carried out at Beijing’s Tisinghua University - demonstrated the flexibility, scalability, cost and energy-efficiency of Alcatel-Lucent’s vRAN and NFV technologies for meeting the dynamically changing demands for access from an ever increasing number of applications and devices, people and machines. This is also an important step in the path towards 5G networks.
It is predictable that the Internet of Things and millions of people connecting to the Internet for the first time will place huge demands on mobile networks over the coming years, with data traffic predicted to enhance almost tenfold between 2014 and 2019[i]. To manage this enhance, China Mobile is preparing for the evolution to 5G, which promises greater network convergence, better spectral efficiency, support for more users, higher data rates and a more comprising user experience.
Alcatel-Lucent provides Internet protocol (IP) and cloud networking, and ultra- broadband access worldwide. The company’s Core Networking segment offers IP routing, carrier Ethernet, network functions virtualization, and software defined networking applications and infrastructure to meet the challenges of network traffic growth while supporting the delivery of cloud-enabled business, mobile, and residential services for service providers, mobile network operators, cable/multiple system operators, transportation, utilities, and large-scale enterprises.
Shares of XOMA Corp (NASDAQ:XOMA), inclined 2.09% to $0.796, during its current trading session.
XOMA Corp (XOMA) declared XOMA 358, a fully human allosteric monoclonal antibody that reduces both the binding of insulin to its receptor and downstream insulin signaling, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of congenital hyperinsulinism (HI).
Orphan drug designation is granted by the FDA Office of Orphan Products Development (OOPD) to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the United States. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity, in addition to tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance, and waiver of Prescription Drug User Fee Act (PDUFA) filing fees. The OOPD also works on rare disease issues with the medical and research communities, professional organizations, academia, governmental agencies, industry, and rare disease patient groups.
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate comprises gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, in addition to diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis.
TE Connectivity Ltd (NYSE:TEL), during its Wednesday’s current trading session gained 1.15% to $61.72.
TE Connectivity world leader in connectivity, declared the QRapid fiber panel, a new version of its Rapid Fiber panel that incorporates Quareo physical layer administration technology comprising connection point identification (CPID) for real-time visibility to network add-ons, moves and changes. This new panel improves speed and efficiency in central office fiber deployments while slashing deployment costs.
The QRapid fiber panel is a 1RU 48-port or 3RU 144-port rack-mountable fiber distribution panel that incorporates TE’s RapidReel fiber cable spool and contains electronics that enable it to function as part of TE’s Quareo physical layer administration system. The functionality of the QRapid fiber panel provides a user with the ability to know in real time whether each front port of the panel is connected, and to what other equipment and port it is connected.
The QRapid fiber panel delivers several key benefits:
- Physical Layer Administration: Expands options for central office and data center network architects who want to gain an accurate, real-time view of the physical network.
- Cost Savings: RapidReel cable spools reduce upfront deployment costs by simplifying site survey inspections, reducing labor hours and streamlining cable deployment.
- Faster Deployment: The pre-connectorized, plug-and-play solution eliminates splice labor requirements and speeds network construction.
- Easy Access: The panel’s technician-friendly, front-facing interface ensures trouble-free maintenance and fast service turn-ups.
TE Connectivity Ltd., together with its auxiliaries, designs and manufactures connectivity and sensors solutions. It operates through four segments: Transportation Solutions, Industrial Solutions, Network Solutions, and Consumer Solutions. The Transportation Solutions segment offers electronic components, counting terminals and connectors, relays, and sensors, in addition to application tooling, wire and heat shrink tubing, and other custom-engineered solutions for the automotive market, such as industrial and commercial vehicle, and hybrid and electric vehicle markets.
Finally, Columbia Pipeline Group Inc (NYSE:CPGX), gained 2.45%, to $28.88.
The Board of Directors of Columbia Pipeline Group, Inc. (CPGX) approved a quarterly dividend payment of 12.5 cents per share, payable August 20, 2015, to common stockholders of record at the close of business July 31, 2015.
Columbia Pipeline Group, Inc., together with its auxiliaries, owns, operates, and develops a portfolio of pipelines, storage, and related midstream assets. It owns about 15,000 miles of interstate gas pipelines from New York to the Gulf of Mexico; and natural gas storage systems with about 300 million dekatherms (MMDth) of working gas capacity, in addition to related gathering and processing assets.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
